3 news items
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AKRO
10 May 24
that is estimated to affect more than 17 million Americans. MASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury
Akero Therapeutics Publishes Phase 2b SYMMETRY Cohort D Study In Clinical Gastroenterology And Hepatology
AKRO
7 Mar 24
alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
AKRO
7 Mar 24
significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results
- Prev
- 1
- Next